Akari Therapeutics Plc — Form 8-K
Filed October 30, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 18/100
What the filing says
Form 8-K filed 2026-10-30 reporting Item 5.07 (Submission of Matters to a Vote of Security Holders) as of 2026-10-28. The filing provides no specific details regarding what matters were submitted, dollar amounts involved, vote counts, or outcomes. Only metadata and XBRL exhibit files are disclosed.
Why this rating
Routine shareholder matter disclosure with no material specifics disclosed. Cannot assess impact without detail on actual vote content or outcomes.
Extracted items
- 5.07 shareholder vote
- 9.01 exhibits
See more from October 30, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.